+ Follow BIBIANE FONTEJON Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1323092
[Title] => Novartis leads Thalassemia Day observance
[Summary] => Novartis Healthcare Philippines partnered with patient support group Balikatang Thalassemia (Ba-Tha) and the Quezon City Health Department to lead the country’s observance of World Thalassemia Day (WTD).
[DatePublished] => 2014-05-15 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 1171651
[Title] => Cancer awareness drive on
[Summary] => Novartis Healthcare Philippines has partnered with the Philippine Society of Medical Oncologists (PSMO), Philippine Society of Hematology and Blood Transfusion (PSHBT), Philippine Charity Sweepstakes Office (PCSO), Philippine Foundation for Breast Care-Kasuso, Touched by Max Philippines and Balikatang Thalassemia to raise cancer awareness and help patients and their family cope with the disease.
[DatePublished] => 2013-09-05 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 862112
[Title] => Novartis drug offers new tack in cancer treatment
[Summary] => Endocrine therapy remains the cornerstone of treatment for postmenopausal women with hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer.
[DatePublished] => 2012-11-01 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] => http://imageshack.us/a/img27/6591/scitec4newthumb.jpg
)
[3] => Array
(
[ArticleID] => 833899
[Title] => Novartis cancer drug gets Phl FDA approval
[Summary] => The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
[DatePublished] => 2012-08-02 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 779855
[Title] => Novartis, NKTI tie up to help GEP NET patients
[Summary] => Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), a form of cancer frequently difficult to diagnose and treat or manage.
[DatePublished] => 2012-02-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
BIBIANE FONTEJON
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1323092
[Title] => Novartis leads Thalassemia Day observance
[Summary] => Novartis Healthcare Philippines partnered with patient support group Balikatang Thalassemia (Ba-Tha) and the Quezon City Health Department to lead the country’s observance of World Thalassemia Day (WTD).
[DatePublished] => 2014-05-15 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 1171651
[Title] => Cancer awareness drive on
[Summary] => Novartis Healthcare Philippines has partnered with the Philippine Society of Medical Oncologists (PSMO), Philippine Society of Hematology and Blood Transfusion (PSHBT), Philippine Charity Sweepstakes Office (PCSO), Philippine Foundation for Breast Care-Kasuso, Touched by Max Philippines and Balikatang Thalassemia to raise cancer awareness and help patients and their family cope with the disease.
[DatePublished] => 2013-09-05 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 862112
[Title] => Novartis drug offers new tack in cancer treatment
[Summary] => Endocrine therapy remains the cornerstone of treatment for postmenopausal women with hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer.
[DatePublished] => 2012-11-01 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] => http://imageshack.us/a/img27/6591/scitec4newthumb.jpg
)
[3] => Array
(
[ArticleID] => 833899
[Title] => Novartis cancer drug gets Phl FDA approval
[Summary] => The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
[DatePublished] => 2012-08-02 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 779855
[Title] => Novartis, NKTI tie up to help GEP NET patients
[Summary] => Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), a form of cancer frequently difficult to diagnose and treat or manage.
[DatePublished] => 2012-02-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
September 5, 2013 - 12:00am
November 1, 2012 - 12:00am
February 23, 2012 - 12:00am
